Bicalutamide (Casodex) 150 mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progression

M. Wirth*, C. Tyrrell, M. Wallace, K. P. Delaere, M. Sánchez-Chapado, J. Ramon, J. Hetherington, F. Pina, C. F. Heynes, T. M. Borchers, T. Morris, A. Stone

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

79 Scopus citations

Fingerprint

Dive into the research topics of 'Bicalutamide (Casodex) 150 mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progression'. Together they form a unique fingerprint.

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science